( )-Pseudoephedrine

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

China proposes new drug registration rules; India eases norms for clinical trials

This week, Phispers brings you contrasting news on two immunotherapy drugs -- Bristol-Myers Squibb&r